Gland Pharma manufactures injectable formulations,

GLAND Strengths - Strong global injectable pharmaceutical business. - Established presence in the US market. - Strong sterile manufacturing capabilities. - Q2 revenue growth of 23%. - PAT growth of 58%. - Improving EBITDA margins. - Strong CDMO business growth. - New product launches in the US. Weaknesses - High dependence on regulated export markets. - US market concentration. - Regulatory compliance requires continuous investment. - High R&D and manufacturing costs. - Quarterly profitability can fluctuate. - Currency movements affect export earnings. Opportunities - Growing global demand for injectable medicines. - Expansion in complex generics and oncology injectables. - CDMO outsourcing opportunities. - New US product approvals and launches. - Ready-to-use injectable bags market opportunity. - Strategic CDMO partnership with a global pharma company. - Sterile API collaboration with Neuland Laboratories. InvestyWise+1 Threats - USFDA regulatory compliance risks. - Generic drug pricing pressure. - Competition from global injectable manufacturers. - Product approval delays. - Currency and export-market risks. - Manufacturing disruption and quality-control risks. - Dundigal facility received 4 USFDA Form 483 observations in October 2026; company described them as procedural and not related to data integrity